Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure. The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg.
Latest News from Moneycontrol.com
Relmada Therapeutics (Nasdaq: RLMD) Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services